ERBB2 and gastric cancer: The gut microbiome composition influences treatment response in HER2-negative advanced gastric cancer patients. High Lactobacillus abundance leads to better response and longer progression-free survival. Lower Streptococcus abundance in immunotherapy plus chemotherapy group improves response and PFS. Lactobacillus may be a potential adjuvant agent for immunotherapy efficacy.